Loading institutional data...
Loading institutional data...
Held by 250 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $22.38 today, the market must believe free cash flow compounds -31.2%/yr for a decade (off $268M normalized FCF).
The market's -31.2% is more conservative than its 7-yr track record.
2-stage DCF · 0.03B shares · net debt -$231M
mean 60.2% · volatility σ 130% · implied rate exceeded in 6/7 yrs
Central path = implied -31.2%/yr growth; shaded band = ±1σ (130%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $780.6M 100.0% | $631.4M 100.0% | $566.8M 100.0% | $463.9M 100.0% | $276.9M 100.0% | $310.0M 100.0% | $296.7M 100.0% | $280.4M 100.0% | $28.5M 100.0% | $1.7M 100.0% |
| Cost of Revenue | $317.3M 40.7% | $254.1M 40.2% | $240.6M 42.5% | $254.4M 54.8% | $126.3M 45.6% | $130.2M 42.0% | $193.7M 65.3% | $165.7M 59.1% | $2.6M 9.1% | $213K 12.4% |
| Cost of Products | — | — | — | — | — | — | — | — | $2.6M 9.1% | $213K 12.4% |
| Gross Profit | $463.3M 59.3% | $377.3M 59.8% | $326.2M 57.5% | $209.5M 45.2% | $150.6M 54.4% | $179.8M 58.0% | $103.0M 34.7% | $114.7M 40.9% | — | — |
| Research & Development | — | $0 0.0% | $0 0.0% | $4.0M 0.9% | $9.5M 3.4% | $9.8M 3.2% | $10.3M 3.5% | $8.7M 3.1% | $8.6M 30.1% | $14.9M 873.6% |
| Selling, General & Admin | $284.8M 36.5% | $210.4M 33.3% | $159.2M 28.1% | $172.2M 37.1% | $119.0M 43.0% | $113.8M 36.7% | $116.4M 39.2% | $126.8M 45.2% | $92.8M 325.7% | $80.6M 4712.6% |
| Total Operating Expenses | $283.6M 36.3% | $207.4M 32.9% | $159.2M 28.1% | $176.2M 38.0% | $133.0M 48.0% | $123.6M 39.9% | $126.8M 42.7% | $135.4M 48.3% | $103.9M 364.9% | $95.8M 5598.7% |
| Operating Income | $179.6M 23.0% | $169.9M 26.9% | $167.0M 29.5% | $33.3M 7.2% | $17.6M 6.4% | $56.2M 18.1% | -$23.7M -8.0% | -$20.7M -7.4% | -$75.4M -264.9% | -$94.1M -5498.7% |
| Interest Expense | $82.3M 10.5% | $74.0M 11.7% | $83.3M 14.7% | $63.2M 13.6% | $21.0M 7.6% | $28.9M 9.3% | $909K 0.3% | $20.1M 7.2% | — | $94K 5.5% |
| Other Income (Expense), net | — | — | — | — | — | — | — | — | $582K 2.0% | -$94K -5.5% |
| Pretax Income | $92.6M 11.9% | $98.6M 15.6% | $75.7M 13.4% | -$28.8M -6.2% | -$3.4M -1.2% | $27.6M 8.9% | -$22.7M -7.7% | -$39.1M -14.0% | — | — |
| Income Tax Expense | $29.7M 3.8% | $29.4M 4.7% | $27.6M 4.9% | -$3.8M -0.8% | -$74.9M -27.0% | $830K 0.3% | $0 0.0% | — | — | — |
| Net Income | $63.0M 8.1% | $69.0M 10.9% | $48.0M 8.5% | -$25.0M -5.4% | $72.0M 26.0% | $26.8M 8.6% | -$22.7M -7.7% | -$39.1M -14.0% | -$74.9M -262.9% | -$94.2M -5504.1% |
| Per Share | ||||||||||
| EPS (Basic) | $1.98 | $2.14 | $1.43 | $-0.74 | $2.05 | $0.78 | $-0.68 | $-1.19 | — | $-3.88 |
| EPS (Diluted) | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 | $0.76 | $-0.68 | $-1.19 | — | — |
| Weighted Avg Shares (Basic) | 31.7M | 32.3M | 33.7M | 33.8M | 34.9M | 34.4M | 33.5M | 33.0M | — | — |
| Weighted Avg Shares (Diluted) | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $25M buybacks = $25M returned on $328M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $231M covers all $12M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2019-03-31 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 11-yr range · 5th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 59.1 | 65.3 | 42.0 | 45.6 | 54.8 | 42.5 | 40.2 | 40.7 |
| Gross Profit | 40.9 | 34.7 | 58.0 | 54.4 | 45.2 | 57.5 | 59.8 | 59.3 |
| R&D | 3.1 | 3.5 | 3.2 | 3.4 | 0.9 | 0.0 | 0.0 | — |
| SG&A | 45.2 | 39.2 | 36.7 | 43.0 | 37.1 | 28.1 | 33.3 | 36.5 |
| Operating Income | -7.4 | -8.0 | 18.1 | 6.4 | 7.2 | 29.5 | 26.9 | 23.0 |
| Income Tax | — | 0.0 | 0.3 | -27.0 | -0.8 | 4.9 | 4.7 | 3.8 |
| Net Income | -14.0 | -7.7 | 8.6 | 26.0 | -5.4 | 8.5 | 10.9 | 8.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on COLL: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| COLL | $710M | 12.9× | 2.6× | 0.9× | 23.6% | 59.3% | 8.1% | 20.8% | 20.8% | — | 250 |
Peers = companies sharing COLL's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.